Princeton Global Asset Management LLC Lowers Holdings in Zoetis Inc. $ZTS

Princeton Global Asset Management LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,371 shares of the company’s stock after selling 180 shares during the period. Princeton Global Asset Management LLC’s holdings in Zoetis were worth $370,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Nova Wealth Management Inc. purchased a new position in Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC increased its holdings in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC lifted its stake in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. UBS Group dropped their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $195.00.

Zoetis Trading Up 0.7%

Shares of Zoetis stock opened at $145.11 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $193.00. The firm has a market capitalization of $64.31 billion, a PE ratio of 24.98, a P/E/G ratio of 2.31 and a beta of 0.90. The firm’s 50-day moving average price is $148.65 and its 200 day moving average price is $153.60.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.